Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Investor Presentation (November 2025)

32 slides from Cellectis's investor presentation, November 2025

  1. Slide 1: Corporate Presentation November 2025

    Corporate Presentation November 2025 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking” statements within the These forward-looking statements are made in light of information meaning of applicable securities laws, including the Private Securities currently available to us and are subject to numerous risks and Liti

  3. Slide 3: Cellectis' Leadership Position in Cell & Gene Therapy

    Cellectis’ Leadership Position in Cell & Gene Therapy INNOVATIVE BEST-IN-CLASS END-TO-END STRONG ALLOGENEIC CAR-T GENE EDITING IN-HOUSE PARTNERSHIPS PLATFORM MANUFACTURING 5 ongoing clinical Diversified Financial programs* Backed by Strong IP Upsides 300+ patients treated** (*) 2 Cellectis fully-own

  4. Slide 4: Cellectis Partners with Industry Leaders; Cash Position $225M

    Cellectis Partners with Industry Leaders Partnerships with industry leaders: $6bn potential milestones + royalties Cash Position Clinical Trials* $225M* as of September 30, 2025 Expected runway into H2 2027 ** *Cash, cash equivalents and fixed-term deposits include restricted cash of $4.4 million as

  5. Slide 5: TALEN is Best-in-class Gene Editing

    TALEN® is Best-in-class Gene Editing NUCLEASE SAFE Low genotoxicity and off-target* Gene replacement, correction, insertion PRECISE Targets precisely any DNA BASE EDITORS Gene editing without CRISPR- associated genotoxicity EFFICIENT High editing efficiencies (up to 100%) GENE MODULATORS VERSATILE V

  6. Slide 6: UCART Design

    UCART Design CD52 KO TCRaβ KO CAR CD52 KO TCRaβ KO Resistance to Minimizes risk CAR-T cell anti-CD52 abs of GvHD Abs: Antibodies ; CART: Chimeric Antigen Receptor T-cell ; GvHD: Graft-versus-Host-Disease ; KO: Knock-Out ; UCART: Universal Chimeric Antigen Receptor T-cell 6

  7. Slide 7: Allogeneic CAR-T: Unlocking a Scalable Industrial Approach

    Allogeneic CAR-T: Unlocking a Scalable Industrial Approach Healthy donor Cell Cell Frozen UCART Patients cell collection modification amplification product Scalable Manufacturing Off-The-Shelf 1 batch = 100s doses Immediate access and Scalable to 1000s doses attractive gross margins 7

  8. Slide 8: Fully Integrated Manufacturing

    Fully Integrated Manufacturing Paris, France Raleigh, NC 14,000 sq ft. facility 82,000 sq ft. facility CMC Development, Starting Materials UCART – Clinical & Intended Ready Site ✓ Process & analytical development ✓ UCART GMP manufacturing Allogeneic CAR-T ✓ Starting materials manufacturing: ✓ QC tes

  9. Slide 9: Advancing an Industry-Leading Pipeline

    Advancing an Industry-Leading Pipeline UPCOMING EXPECTED STUDY INDICATION PRECLINICAL PHASE 1 PHASE 21 MILESTONE BALLI-01 Pivotal Phase 2 first interim analysis B-ALL expected in Q4 2026 Lasme-cel (CD22) Fully Owned NATHALI-01 NHL Full Phase 1 dataset expected in Eti-cel (CD20, CD22) 2026 ALPHA 3 LB

  10. Slide 10: Lasme-cel and Eti-cel Differentiated Positioning

    Lasme-cel and Eti-cel Differentiated Positioning LCAR-AIO CD19/CD20/CD22 Post-CD19 CAR-T KITE-363/ KITE-753 autologous CD19/CD20 treatments ▪ CD20 & CD22: Differentiated targets validated in oncology C-CARO39 CD19/CD20 ▪ Lasme-cel: Best-in-class allogeneic CD22 CAR-T for B-ALL. ▪ Eti-cel: Unique all

  11. Slide 11: Lasme-cel for patients with relapsed or refractory B-ALL

    Lasme-cel for patients with relapsed or refractory B-ALL Lasme-cel is not FDA approved 11

  12. Slide 12: B-ALL: an Unmet Medical Need

    B-ALL: an Unmet Medical Need B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA • 1L treated population: ~9,200 Patients (US, EU4, UK)* High relapse in adults CHALLENGES WITH EXISTING TREATMENTS • Chemotherapies: Lead to high relapse rate in adults • ADCs have a limited effect: Low antigen expression • CD19-direct

  13. Slide 13: Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL?

    P13 Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL? Allogeneic CAR-T Starts with Healthy-donor T Cells Healthier and less exhausted than autologous cells from heavily pretreated patients Off-the-Shelf is designed for “Speed” – in B-ALL Every Day Counts Standardized, Repeatable Quality All p

  14. Slide 14: Poor Response Rates after Targeted Therapy Failure

    Poor Response Rates after Targeted Therapy Failure 1 After targeted therapy failure, salvage chemo yields low ORR and MRD: High unmet need in heavily Post Blina failure Post Ino failure Post CAR-T failure pretreated patients ORR <20% ORR <10-15% ORR <10% MRD-ve <10% MRD-ve <5-10% MRD-ve <5% 1. Inter

  15. Slide 15: BALLI-01 Demographic and Baseline Characteristics

    BALLI 01 | Demographic and Baseline Characteristics DL3 P2 All Subjects (n=12) Age ≤ 50 (n=9) Total (n=40) Age (yrs), median (range) 27 (16 - 66) 23 (16 - 45) 27 (16 - 68) Sex, n (%) Male 5 (41.7) 3 (33.3) 22 (55) Female 7 (58.3) 6 (66.7) 18 (45) ECOG PS, n (%) 0 5 (41.7) 4 (44.4) 14 (35) 1 6 (50) 4

  16. Slide 16: High Response Rates in P2 Cohort

    High Response Rates in P2 Cohort Overall Response Rate (%) 100% 100 90 83% Cellectis manufactured 80 44% product (P2) is superior 68% 70 to CDMO product (P1) 60 41% 50 32% 40 28% Recommended Phase 30 56% 6% 2 Dose: DL3 20 36% 42% 10 22% 0 Target Phase 2 P1(n=18) P1 (n=18 P2 (n=22) P2 DL3 (n=12) Targ

  17. Slide 17: High Response Rates in P2 Cohort

    High Response Rates in P2 Cohort CR/CRi rate with MRD status (%) 60 56% 50 11% 42% 40 36% In Target Phase 2 8% 9% population, 30 22% 80% who achieved 20 45% CR/CRi were also 11% 34% 27% MRD negative 10 11% 0 P1 (n=18 (n=18) P2 (n=22) P2 DL3 (n=12) Target Pivotal Phase 2 Population (n=9) MRD-ve CR/CR

  18. Slide 18: Achieving Transplant: an Important Clinical Outcome

    Achieving Transplant: an Important Clinical Outcome Subjects Who Received or Eligible for HSCT (%) 100 90 20% 80 100% 70 Received or 60 Eligible for 50 HSCT 40 80% 75% 30 55% 50% In Phase 2 target 20 population 10 17% 0 P2 Overall P2 DL2 (n=6) P2 DL2i (n=4) P2 DL3 (n=12) Target Pivotal (n=22) Phase

  19. Slide 19: Improved Survival in Patients Who Responded

    Improved Survival in Patients Who Responded Overall Survival over 12 months by Response (P2) Median Overall Survival in Subjects who Achieve MRD- negative CR/CRi 16 14.8 14.8 14 12 10 9.4 Months 8 6 4 2 0 P2 DL3 Target Pivotal Phase 2 Population P2 14.8 months DL3 Median overall survival in subjects

  20. Slide 20: High CR/CRi Rates in Patients Exposed to Prior Targeted Therapies

    High CR/CRi Rates in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T CR/CRi Rate (in %) in Patients with Prior Exposure to 3 Targeted Therapies: Blin, Ino and CD19 CAR-T 80 70 Deep 60 responses if 50 received all 3 available 40 75% targeted 30 60% therapies 20

  21. Slide 21: Low Incidence of Grade ≥3 CRS and ICANS

    Low Incidence of Grade ≥ 3 CRS and ICANS CRS and ICANS: Total Population (n=40) CRS and ICANS: DL3 (n=18) 100 100 90 90 80 5.5 80 70 2.5 Percentage (%) 70 60 39 60 32.5 50 50 40 40 12 30 30 12 20 39 20 37.5 5 10 10 10 17 7.5 0 0 CRS ICANS CRS ICANS Grade1 Grade 2 Grade 3 Grade1 Grade 2 Grade 3 ICANS

  22. Slide 22: No Current Signal for IEC-HS

    No Current Signal for IEC-HS Significant interest in the risk of IEC-HS based on prior CD22 targeting autologous CAR-T ▪One case observed in BALLI-01 No evidence of IEC-HS ▪Grade 2 HLH Day 5 CD22 target incidence ▪Resolved with related effect Anakinra/Dex IEC-HS: Immune Effector Cell–Associated Hemo

  23. Slide 23: Study Design: Pivotal Phase 2

    Study Design: Pivotal Phase 2 Interim Analysis 1: Interim Analysis 2: Primary Analysis Overall Dose Optimization 50% pivotal Cohort for BLA Survival Primary Endpoint: CR / CRi, evaluated within 3 months (from Day 28 to Day 84) Age 12-50 years Recruitment of patients driven by 75 planned study center

  24. Slide 24: Multiple Catalysts to 2H 2028

    Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 BLA: Biologics Licence Application 24

  25. Slide 25: Lasme-cel Has the Potential to Reach Up To ~1.9K Addressable 3L+ Patients

    Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45

  26. Slide 26: Lasme-cel Could Achieve Up To ~$700M in Peak Gross Sales

    Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales (U.S., EU4, UK) Assumption Source / Rationale Addressable Patients (#) ~1.1 K ~840 Represents expected 3L CAR-T eligible patients in 2035 x x • Triangulated using physician-reported preferences and average market share of Preference Share (%)

  27. Slide 27: Eti-cel for patients with relapsed or refractory NHL

    Eti-cel for patients with relapsed or refractory NHL Eti-cel is not FDA approved 27

  28. Slide 28: Eti-cel: Study Design

    Eti-cel: Study Design Dose Escalation Key inclusion criteria: Dose Expansion ▪ Age 18–80 years BOIN design • 2-4 pts/cohort ▪ Mature B-cell NHL except CLL/SLL, Richter’s from CLL/SLL, Burkitt’s lymphoma, or Waldenstrom’s macroglobulinemia 450 × 10 6 cells DL 3 ▪ Tumor positive for CD20 and/or CD22 ▪

  29. Slide 29: Eti-cel: High Response Rates in R/R NHL

    Eti-cel: High Response Rates in R/R NHL Response rate (%) [n=7] 100 90 80 70 4/7 CR at 60 Current 50 86% 40 Dose Level 30 57% 20 10 0 ORR CR Update on Program at ASH 2025 29 ASH: American Society of Hematology annual congress

  30. Slide 30: Expected 2026 Catalysts

    Expected 2026 Catalysts Lasme-cel Phase 2 first Interim Analysis Eti-cel Potential EoP1 in r/r NHL Preclinical PoC for In Vivo Gene Therapy EoP1: End-of-Phase 1 ; PoC: Proof-of-Concept 30

  31. Slide 31: Thank You

    Thank You Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA 31 Cellectis®, TALEN® and our corporate logos are registered

  32. Slide 32: Diversified Partnerships with Industry Leaders

    Diversified Partnerships with Industry Leaders CAR-T CAR-T BCMA, CD70 TILs Cell and Gene Therapies CD19 (ALLO-501, Cema-cel) + 13 targets Exclusive worldwide U.S. rights exclusively Exclusive worldwide Research Joint Research and license to CD19- sublicensed to license to 15 collaboration and Collab

Cellectis — Investor Presentation (November 2025) on 6ix